The Challenge: rare aggressive cancer-driving cells in heterogeneous tumors survive therapy and cause patient relapse

Tumor diagnosis >

Pre-existing tumor heterogeneity

Cancer therapy >

Chemotherapy / immuno-therapy

Patient remission >

Cancer therapy induced reduction of tumor tissue

Cancer metastasis >

Expansion of cancer-driving cell population

Patient relapse >

Progressed cancer with no therapies available yet

Based on: Dagogo-Jack and Shaw 2018: “Tumour heterogeneity and resistance to cancer therapies”, Nature reviews Clinical oncology

50% of cancer patients are still dying due to treatment failure and relapse

Low resolution and absence of traditional surface markers prevented dedicated cancer-driving cell research up until now


Rare cancer cell subtype

Limited presence and resolution for analysis of cancer-driving cells in mixed tumor cell populations resulting in too much noise

Limited availability cell surface markers

Selection and isolation of cells of interest for further analysis including single cell sequencing is subject to the presence of traditional cell surface markers